Body mass index influences the response to infliximab in ankylosing spondylitis. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Arthritis Research and Therapy Year : 2012

Body mass index influences the response to infliximab in ankylosing spondylitis.

Marine Forien
  • Function : Author
  • PersonId : 926008
Anaïs Gardette
  • Function : Author
  • PersonId : 926009
Blandine Pasquet
  • Function : Author
  • PersonId : 926010
Elisabeth Palazzo
  • Function : Author
  • PersonId : 926011
Marine Meunier
  • Function : Author
  • PersonId : 926012
Gilles Hayem
  • Function : Author
  • PersonId : 926013
Chantal Job-Deslandre
  • Function : Author
  • PersonId : 926014
André Kahan
  • Function : Author
  • PersonId : 926015
Olivier Meyer
  • Function : Author
  • PersonId : 918405


ABSTRACT: INTRODUCTION: The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetic consequences. The aim of this study was to determine whether body mass index (BMI) affects response to infliximab (IFX) in ankylosing spondylitis (AS) patients. METHODS: In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX treatment (5 mg/kg intravenously). After 6 months of treatment, changes from baseline in BASDAI, Visual Analogue Scale (VAS) pain, C-reactive protein (CRP) level and total dose of Nonsteroidal anti-inflammatory drug (NSAID) was dichotomized with a threshold corresponding to a decrease of 50% of initial level of the measure, into binary variables assessing response to IFX (BASDAI50, VAS50, CRP50, NSAID50). Whether BMI was predictive of response to IFX therapy according to these definitions was assessed with logistic regression. RESULTS: Multivariate analysis found a higher BMI was associated with a lower response for BASDAI50 (P=0.0003, OR 0.87 95%CI0.81-0.94VAS50 (P<0.0001, OR 0.87 95%CI[0.80-0.93]), CRP50 (P=0.0279, OR 0.93 95%CI0.88-0.99) and NSAID50 (P=0.0077, OR 0.91 95%CI0.85-0.97criteria. According to the 3 WHO BMI categories, similar results were found for BASDAI50 (77.6%, 48.9% and 26.5%, P<0.0001), VAS50 (72.6%, 40.4% and 16.7%, P<0.0001), CRP50 (87.5%, 65.7% and 38.5%, P=0.0001) and NSAID50 (63.2%, 51.5% and 34.6%, P=0.06). CONCLUSIONS: This study provides the first evidence that a high BMI negatively influences the response to IFX in AS. Further prospective studies, including assessment of the fat mass, pharmacokinetics and adipokines dosages are mandatory to elucidate the role of obesity in AS IFX response.
Fichier principal
Vignette du fichier
ar3841.pdf (242.26 Ko) Télécharger le fichier
ar3841.xml (54.25 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Dates and versions

inserm-00704843 , version 1 (06-06-2012)



Sébastien Ottaviani, Yannick Allanore, Florence Tubach, Marine Forien, Anaïs Gardette, et al.. Body mass index influences the response to infliximab in ankylosing spondylitis.. Arthritis Research and Therapy, 2012, 14 (3), pp.R115. ⟨10.1186/ar3841⟩. ⟨inserm-00704843⟩
225 View
458 Download



Gmail Facebook Twitter LinkedIn More